Levels of VEGF but not VEGF(165b) are increased in the vitreous of patients with retinal vein occlusion.

Autor: Ehlken C; Augenklinik, Universitätsklinikum Freiburg, Freiburg, Germany., Rennel ES, Michels D, Grundel B, Pielen A, Junker B, Stahl A, Hansen LL, Feltgen N, Agostini HT, Martin G
Jazyk: angličtina
Zdroj: American journal of ophthalmology [Am J Ophthalmol] 2011 Aug; Vol. 152 (2), pp. 298-303.e1. Date of Electronic Publication: 2011 May 28.
DOI: 10.1016/j.ajo.2011.01.040
Abstrakt: Purpose: To determine the concentration of the pro-angiogenic vascular endothelial growth factor VEGF(165) (VEGF) and the anti-angiogenic VEGF(165b) in vitreous samples of patients with branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) in comparison to patients without retinal occlusive disease.
Design: Experimental laboratory investigation.
Methods: Vitreous samples were collected from patients undergoing surgery for arteriovenous dissection after BRVO, radial optic neurotomy after CRVO in the occlusion group, or macular pucker or macular hole in the control group. Concentrations of VEGF and VEGF(165b) were determined by ELISA and an ELISA-type antibody microarray.
Results: Average vitreal concentration of VEGF was 8.6 ng/mL in the CRVO group and 2.0 ng/mL in the BRVO group as compared to 0.26 ng/mL in the control group. Average vitreal concentration of VEGF(165b) was 27 pg/mL in the CRVO group, 42 pg/mL in the BRVO group, and 49 pg/mL in the control group. In patients with CRVO and BRVO, the angiogenic balance was shifted towards angiogenic stimulation.
Conclusion: The severity of RVO from BRVO to CRVO correlates with an increase of VEGF and the decrease of VEGF(165b), indicating a pro-angiogenic shift. Altering the ratio of VEGF(165b)/VEGF(165) might be a feasible approach for treating retinal occlusive diseases.
(Copyright © 2011 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: